Scholarlink

<p>Research is undertaken to identify alternate sources of DPP-IV inhibitors that could protect the beta cell function and assess its therapeutic potential in prediabetes. This study formulated a polyherbal tablet of medicinal plants made from <i>Terminalia arjuna</i>, <i>Commiphora mukul</i>, and <i>Phyllanthus emblica</i> with DPP-IV inhibitory activity and evaluated its cardiometabolic efficacy and mechanisms in setting of prediabetes compared to those of the standard medicine metformin. Prediabetes was induced in rats by using high-fat–high-carbohydrate diet, 25% fructose and vanaspati ghee, coconut oil 3:1 ratio. The polyherbal combination (1000 mg/kg) and metformin (500 mg/kg) was orally administered. Blood glucose, HbA1c, lipid profile, liver, kidney, cardiac markers of injury, and histopathological studies were undertaken. Insulin, HOMA-IR, HOMA-beta, atherogenic index, and DPP-IV levels were estimated to elucidate the mechanism of action. Plain uncoated polyherbal tablet was formulated and bio-standardization undertaken using HPTLC. The glucose-lowering efficacy of the polyherbal combination was found to be equivalent to metformin. Interestingly, the cardioprotective efficacy was superior than metformin. The hypolipidemic, DPP-IV inhibitory activity, favorable effects on beta cell function, insulin resistance, atherogenic index may contribute to the beneficial effects of polyherbal combination. The polyherbal tablet was found to be safe. Polyherbal combination demonstrated significant DPP-IV inhibitory and cardiometabolic effects in the experimental model of prediabetes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative Cardiometabolic Effects of Polyherbal Formulation with Dipeptidyl Peptidase IV Inhibitory Activity Versus Metformin in Experimental Prediabetes

  • 期刊论文

  • 发表日期：

    2025年2月28日

查看全文
  • Ujwala Dhanawade,
  • Ipseeta Ray Mohanty,
  • Ujwala Maheshwari,
  • Prithviraj Erande

摘要

Research is undertaken to identify alternate sources of DPP-IV inhibitors that could protect the beta cell function and assess its therapeutic potential in prediabetes. This study formulated a polyherbal tablet of medicinal plants made from Terminalia arjuna, Commiphora mukul, and Phyllanthus emblica with DPP-IV inhibitory activity and evaluated its cardiometabolic efficacy and mechanisms in setting of prediabetes compared to those of the standard medicine metformin. Prediabetes was induced in rats by using high-fat–high-carbohydrate diet, 25% fructose and vanaspati ghee, coconut oil 3:1 ratio. The polyherbal combination (1000 mg/kg) and metformin (500 mg/kg) was orally administered. Blood glucose, HbA1c, lipid profile, liver, kidney, cardiac markers of injury, and histopathological studies were undertaken. Insulin, HOMA-IR, HOMA-beta, atherogenic index, and DPP-IV levels were estimated to elucidate the mechanism of action. Plain uncoated polyherbal tablet was formulated and bio-standardization undertaken using HPTLC. The glucose-lowering efficacy of the polyherbal combination was found to be equivalent to metformin. Interestingly, the cardioprotective efficacy was superior than metformin. The hypolipidemic, DPP-IV inhibitory activity, favorable effects on beta cell function, insulin resistance, atherogenic index may contribute to the beneficial effects of polyherbal combination. The polyherbal tablet was found to be safe. Polyherbal combination demonstrated significant DPP-IV inhibitory and cardiometabolic effects in the experimental model of prediabetes.